Pinoresinol diglucoside exhibits protective effect on dexamethasone-induced osteoporosis in rats
| العنوان: | Pinoresinol diglucoside exhibits protective effect on dexamethasone-induced osteoporosis in rats |
|---|---|
| المؤلفون: | Jian-ming Zhong, Zhan-Feng Zhang, Ji-kang Min, Dan Wang |
| المصدر: | Tropical Journal of Pharmaceutical Research; Vol 15, No 11 (2016); 2451-2457 |
| بيانات النشر: | African Journals Online (AJOL), 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | musculoskeletal diseases, 0301 basic medicine, medicine.medical_specialty, Osteoporosis, Pharmaceutical Science, 030209 endocrinology & metabolism, Bone tissue, Bone remodeling, 03 medical and health sciences, 0302 clinical medicine, Osteoprotegerin, Internal medicine, medicine, Pharmacology (medical), Dexamethasone, Bone mineral, biology, Chemistry, medicine.disease, 030104 developmental biology, Endocrinology, medicine.anatomical_structure, RANKL, biology.protein, Alkaline phosphatase, Pinoresinol diglucoside, Osteoporosis, Bone mass, Bone metabolism, Dexamethasone, Osteoprotegerin, medicine.drug |
| الوصف: | Purpose: To investigate the effect of pinoresinol diglucoside (PDG) on dexamethasone-induced osteoporosis in rats. Methods: Sixty Wistar rats were randomly and equally divided into normal, control, alendronate and PDG (10, 20 or 40 mg/kg) groups. Bone tissue parameters, including length, transverse diameter, weight, bone mineral content (BMC) and bone mineral density (BMD), were determined using vernier caliper, electronic balance and single photon bone mineral density meter. Serum biochemical indices, including Ca 2+ , inorganic phosphorus (IP), IL-6, TNF-α and alkaline phosphatase (ALP), were determined using colorimetry and enzyme-linked immunosorbent assay (ELISA). Osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL) proteins were detected by Western blot. Results: PDG (10, 20 or 40 mg/kg) increased significantly (p < 0.05 or 0.01) transverse diameter (3.64 – 3.79 vs. 3.31 mm), weight (0.73 – 0.78 vs. 0.67 g), BMC (0.16 – 0.23 vs. 0.12 g/cm), BMD (0.27 – 0.35 vs. 0.22 g/cm 2 ) of right femur, serum Ca 2+ level (2.16 – 2.39 vs. 1.94 mmol/L), and OPG level of left femur, compared with those in the control group. PDG (10, 20 or 40 mg/kg) reduced significantly (p < 0.05 or 0.01) serum IP (1.34 – 1.14 vs. 1.76 mmol/L), IL-6 (103.25 – 95.38 vs. 108.74 ng/L), TNF-α (87.46 – 82.05 vs. 92.38 ng/L), ALP (334.79 – 276.32 vs. 486.45 U/L) levels or activities, and RANKL level of left femur, compared with those in the control group. Conclusion: PDG exhibits a protective effect on dexamethasone-induced osteoporosis by increasing bone mass and regulating bone metabolism. Thus, PDG may be a candidate drug for treating osteoporosis. Keywords: Pinoresinol diglucoside, Osteoporosis, Bone mass, Bone metabolism, Dexamethasone, Osteoprotegerin |
| وصف الملف: | application/pdf |
| تدمد: | 1596-9827 1596-5996 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72c81697a21422bf5169a45dc727607bTest https://doi.org/10.4314/tjpr.v15i11.21Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....72c81697a21422bf5169a45dc727607b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15969827 15965996 |
|---|